PMID- 7706986
OWN - NLM
STAT- MEDLINE
DCOM- 19950510
LR  - 20190709
IS  - 0022-0795 (Print)
IS  - 0022-0795 (Linking)
VI  - 144
IP  - 2
DP  - 1995 Feb
TI  - 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of 
      recurrent medullary thyroid carcinoma.
PG  - 339-45
AB  - Detection of recurrence from medullary thyroid carcinoma (MTC) remains a 
      diagnostic problem, especially when increased serum tumour marker levels suggest 
      recurrence and conventional imaging techniques are non-diagnostic. In this study, 
      we performed 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid (DMSA) scans 
      in a series of eleven patients with MTC presenting with elevated serum tumour 
      markers after surgery. 111In-octreotide whole body studies detected tumour in six 
      of the eleven patients studied and detected nine tumoral localizations. 
      99mTc(V)-DMSA whole body studies detected tumour in five of the eleven patients 
      studied and eight tumoral localizations. 111In-octreotide and 99mTc(V)-DMSA 
      studies detected recurrence in all four patients with basal calcitonin levels 
      above 1000 ng/l. We conclude that 111In-octreotide and 99mTc(V)-DMSA studies have 
      limited sensitivity to detect recurrence in patients with MTC, although their 
      sensitivity may improve with high serum calcitonin levels. These radionuclide 
      imaging techniques should be employed when conventional imaging techniques are 
      negative or inconclusive or, in the case of 111In-octreotide studies, should be 
      employed when we went to investigate the presence of somatostatin receptors that 
      provide the basis for treatment with somatostatin analogues.
FAU - Berna, L
AU  - Berna L
AD  - Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, 
      Spain.
FAU - Cabezas, R
AU  - Cabezas R
FAU - Mora, J
AU  - Mora J
FAU - Torres, G
AU  - Torres G
FAU - Estorch, M
AU  - Estorch M
FAU - Carrio, I
AU  - Carrio I
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Endocrinol
JT  - The Journal of endocrinology
JID - 0375363
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Organotechnetium Compounds)
RN  - 142694-57-3 (SDZ 215-811)
RN  - 494JNQ8L28 (Technetium Tc 99m Dimercaptosuccinic Acid)
RN  - 7A314HQM0I (Pentetic Acid)
RN  - 9007-12-9 (Calcitonin)
RN  - DX1U2629QE (Succimer)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/blood
MH  - Calcitonin/blood
MH  - Carcinoma, Medullary/blood/*diagnostic imaging
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/blood/*diagnostic imaging
MH  - Octreotide/*analogs & derivatives
MH  - *Organotechnetium Compounds
MH  - Pentetic Acid/*analogs & derivatives
MH  - Radionuclide Imaging
MH  - *Succimer
MH  - Technetium Tc 99m Dimercaptosuccinic Acid
MH  - Thyroid Neoplasms/blood/*diagnostic imaging
EDAT- 1995/02/01 00:00
MHDA- 1995/02/01 00:01
CRDT- 1995/02/01 00:00
PHST- 1995/02/01 00:00 [pubmed]
PHST- 1995/02/01 00:01 [medline]
PHST- 1995/02/01 00:00 [entrez]
AID - 10.1677/joe.0.1440339 [doi]
PST - ppublish
SO  - J Endocrinol. 1995 Feb;144(2):339-45. doi: 10.1677/joe.0.1440339.